Loading data for RNXT — first visit, this takes a few seconds.
RenovoRx, Inc. (RNXT)
NasdaqCM: RNXT
· 即時價格 · USD
2.39
+0.02 (0.84%)
收盤價： Sep 11, 2026, 3:59 PM
1.82
+3.35%
盤後: 7:42 PM
股價、關鍵數字和最新消息，都在這一頁。
RenovoRx, Inc.（RNXT）股價、分析與資料
0.84% (1D)
| 買價 | 1.83 |
| 市值 | 79.4M |
| 營收 (ttm) | 1.98M |
| 淨利（ttm） | -12.3M |
| 1.12 | |
| -0.31 | |
| n/a | |
| -14.67 | |
| P/B (ttm) | 8.84 |
| P/S (ttm) | 40.20 |
| 財報日期 | Aug 14, 2025 |
| 賣價 | 2.42 |
| 成交量 | 2,092,365 |
| 20 日平均成交量 | 593,887 |
| 開盤價 | 2.35 |
| 前收盤價 | 2.37 |
| 當日區間 | 2.28 - 2.54 |
| 52 週範圍 | 0.70 - 2.59 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 RNXT
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, Calif...
完整的公司簡介財報驚奇
RenovoRx 已於 Aug 12, 2026 公布季度財報：
- 營收為 $909K 低於預期 $0, 年增 115.40% 成長.
- 每股盈餘為 -0.05 超出預期 0.02, 年增 37.50% 成長.
第 1 頁，共 2 頁